Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
OS Therapies (NYSE-A: OSTX) has announced a $6 million private placement, selling 1.5 million units at $4.00 per unit. Each unit includes one share of Series A Senior Convertible Preferred Stock and one warrant to purchase common stock. The Preferred Stock conversion price is $4.00, with warrants exercisable at $4.40 per share.
The placement, expected to close around December 27, 2024, will provide funding into 2026. The proceeds will support clinical and regulatory milestones for OST-HER2, the company’s lead therapeutic candidate for recurrent, resected metastatic osteosarcoma. Phase 2b data for OST-HER2 will be announced during the JP Morgan Healthcare Conference in January 2025.
OS Therapies (NYSE-A: OSTX) ha annunciato un collocamento privato da 6 milioni di dollari, vendendo 1,5 milioni di unità a 4,00 dollari per unità. Ogni unità include una azione di Azioni Preferenziali Convertibili Senior di Serie A e un warrant per l’acquisto di azioni ordinarie. Il prezzo di conversione delle Azioni Preferenziali è di 4,00 dollari, con warrants esercitabili a 4,40 dollari per azione.
Il collocamento, previsto per chiudere intorno al 27 dicembre 2024, fornirà finanziamenti fino al 2026. I proventi supporteranno traguardi clinici e normativi per OST-HER2, il principale candidato terapeutico dell’azienda per l’osteosarcoma metastatico ricorrente e reseccato. I dati della Fase 2b per OST-HER2 saranno annunciati durante la Conferenza Sanitaria di JP Morgan a gennaio 2025.
OS Therapies (NYSE-A: OSTX) ha anunciado una colocación privada de 6 millones de dólares, vendiendo 1.5 millones de unidades a 4.00 dólares por unidad. Cada unidad incluye una acción de Acciones Preferentes Convertibles Senior de Serie A y un warrant para la compra de acciones ordinarias. El precio de conversión de las Acciones Preferentes es de 4.00 dólares, con warrants ejercitables a 4.40 dólares por acción.
La colocación, que se espera cierre alrededor del 27 de diciembre de 2024, proporcionará financiamiento hasta 2026. Los ingresos apoyarán hitos clínicos y regulatorios para OST-HER2, el principal candidato terapéutico de la empresa para el osteosarcoma metastásico recidivante y reseccionado. Los datos de la Fase 2b para OST-HER2 se anunciarán durante la Conferencia de Salud de JP Morgan en enero de 2025.
OS Therapies (NYSE-A: OSTX)는 을 발표하며, 1.5 백만 개 유닛을 개당 4.00 달러에 판매합니다. 각 유닛에는 A 시리즈 상환 가능한 우선주 1주와 일반주를 매입할 수 있는 워런트 1개가 포함되어 있습니다. 우선주의 전환 가격은 4.00 달러, 워런트는 주당 4.40 달러에 행사가능합니다.
이번 공모는 2024년 12월 27일 즈음 마감될 예정이며, 2026년까지 자금을 지원합니다. 수익은 OST-HER2에 대한 임상 및 규제 이정표를 지원하는 데 사용됩니다. OST-HER2의 2b 단계 데이터는 2025년 1월 JP 모건 헬스케어 회의에서 발표될 것입니다.
OS Therapies (NYSE-A: OSTX) a annoncé un placement privé de 6 millions de dollars, vendant 1,5 million d’unités à 4,00 dollars par unité. Chaque unité comprend une action d’Actions Préférentielles Convertibles Senior de Série A ainsi qu’un warrant pour l’achat d’actions ordinaires. Le prix de conversion des Actions Préférentielles est de 4,00 dollars, avec des warrants exerçables à 4,40 dollars par action.
Le placement, qui devrait se clôturer aux alentours du 27 décembre 2024, fournira des financements jusqu’en 2026. Les recettes soutiendront les jalons cliniques et réglementaires pour OST-HER2, le principal candidat thérapeutique de l’entreprise pour l’ostéosarcome métastatique récurrent et réséqué. Les données de la phase 2b pour OST-HER2 seront annoncées lors de la Conférence de Santé de JP Morgan en janvier 2025.
OS Therapies (NYSE-A: OSTX) hat eine Privatplatzierung in Höhe von 6 Millionen Dollar angekündigt und verkauft 1,5 Millionen Einheiten zu einem Preis von 4,00 Dollar pro Einheit. Jede Einheit beinhaltet eine Aktie der Serie A Senior Wandelschuldverschreibungen und ein Warrant zum Kauf von Stammaktien. Der Umwandlungspreis der Vorzugsaktien beträgt 4,00 Dollar, wobei die Warrants zu einem Preis von 4,40 Dollar pro Aktie ausgeübt werden können.
Die Platzierung, die voraussichtlich rund um den 27. Dezember 2024 geschlossen wird, wird bis 2026 Finanzmittel bereitstellen. Die Erlöse werden klinische und regulatorische Meilensteine für OST-HER2, das führende therapeutische Kandidat des Unternehmens für rezidiviertes, reseziertes metastatisches Osteosarkom, unterstützen. Die Phase-2b-Daten für OST-HER2 werden während der JP Morgan Healthcare Conference im Januar 2025 bekannt gegeben.
Positive
- Secured $6 million in funding providing runway into 2026
- 95% of investment from Pre-IPO and/or IPO investors showing strong institutional confidence
- FDA granted rare pediatric disease, fast track and orphan drug designations for OST-HER2
Negative
- Potential dilution for existing shareholders through new share issuance
- Additional warrants at $4.40 could cause further dilution if exercised
Insights
This $6 million private placement represents a strategic capital raise for OS Therapies, providing important runway extension into 2026. The pricing structure at $4.00 per unit with a $4.40 warrant exercise price suggests a 10% premium, indicating investor confidence in future value appreciation. The deal structure, combining convertible preferred stock with warrants, offers downside protection while maintaining upside potential for investors.
The participation of 95% existing pre-IPO/IPO investors signals strong institutional backing and validates the company’s progress. With a current market cap of $81.3 million, this financing represents approximately 7.4% dilution but provides essential capital for advancing OST-HER2 toward potential commercialization. The multiple FDA designations (rare pediatric disease, fast track, orphan drug) enhance the probability of regulatory success and potential market exclusivity.
The timing of this raise ahead of Phase 2b data readout in January 2025 is strategic, securing funding before a major catalyst that could significantly impact valuation. For a small-cap biotech, maintaining sufficient cash runway through key milestones is important for negotiating position and avoiding distressed financing scenarios.
The upcoming Phase 2b data readout for OST-HER2 in recurrent, resected metastatic osteosarcoma represents a pivotal moment for OS Therapies. The triple FDA designations significantly de-risk the regulatory pathway and could accelerate approval timeline. Osteosarcoma, particularly in the recurrent setting, represents a high unmet medical need with treatment options.
The company’s focus on commercialization preparation in 2025 suggests confidence in their clinical data. The strategic allocation of funds primarily toward clinical and regulatory milestones indicates a well-defined pathway to market. For context, osteosarcoma affects approximately 800-900 new patients annually in the US and with competition and potential orphan drug exclusivity, this could represent a significant market opportunity despite the small patient population.
- Funding will provide Company sufficient cash runway into 2026
- 95% of investment in private placement from Pre-IPO and/or IPO investors
- Data from OST-HER2 Phase 2b in recurrent, resected metastatic osteosarcoma to be announced during the week of the JP Morgan Healthcare Conference in January 2025
NEW YORK–(BUSINESS WIRE)– OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has entered into securities purchase agreements with investors to sell 1.5 million units at a price of $4.00 per unit, with each unit consisting of one share of Series A Senior Convertible Preferred Stock (“the Preferred Stock”) initially convertible into one share of common stock and one warrant to purchase one share of common stock, expected to yield gross proceeds to the Company of $6 million, before deducting offering-related expenses. The conversion price of the Preferred Stock into shares of common stock is $4.00 and the exercise price of the warrants is $4.40 per share. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions.
The Company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory milestones to support commercialization of the Company’s lead therapeutic candidate OST-HER2 in the treatment of recurrent, resected metastatic osteosarcoma in the United States in 2025, and for general corporate purposes. The FDA has granted OST-HER2 rare pediatric disease, fast track and orphan drug designations.
Brookline Capital Markets, a division of Arcadia Securities, LLC, served as placement agent and Ceros Financial Services, Inc. was engaged as a selected dealer to the placement agent.
The securities being issued and sold in the private placement, as well as the common shares the securities are convertible or exercisable into, have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. The Company has agreed to file a registration statement with the Securities and Exchange Commission (the SEC”) registering the resale of the shares of common stock issued in this private placement (the “Resale Shares”).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the Resale Shares under the resale registration statement will only be by means of a prospectus.
For more information, please see the Company’s website at www.ostherapies.com.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts included in this press release, including, but not limited to, OS Therapies’ expectations regarding the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the expected receipt and intended uses of the proceeds from the private placement, are forward-looking statements. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, uncertainties related to market conditions and the completion of the private placement on the anticipated terms or at all; the expected future balances of the Company’s cash, cash equivalents and short-term investments; the expected duration over which the Company’s cash, cash equivalents and short-term investments balances will fund its operations; and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Forward-looking statements reflect our analysis only on their stated date, and OS Therapies takes no obligation to update or revise these statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241224858078/en/
Jack Doll
+1-410-297-7793
Source: OS Therapies, Inc.
FAQ
What is the size and price of OS Therapies (OSTX) private placement announced in December 2024?
OS Therapies announced a $6 million private placement, selling 1.5 million units at $4.00 per unit.
When will OS Therapies (OSTX) announce Phase 2b data for OST-HER2?
OS Therapies will announce OST-HER2 Phase 2b data during the JP Morgan Healthcare Conference in January 2025.
What regulatory designations has the FDA granted to OSTX’s OST-HER2?
The FDA has granted OST-HER2 rare pediatric disease, fast track and orphan drug designations.
How long will the $6 million private placement funding extend OSTX’s cash runway?
The funding will provide OS Therapies with sufficient cash runway into 2026.
What are the conversion and warrant exercise prices in OSTX’s private placement?
The Preferred Stock conversion price is $4.00 per share, and the warrant exercise price is $4.40 per share.
